Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26113
Abstract: Chimeric antigen receptor T‐cell therapy (CAR T) is a novel intervention for relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) and other hematologic malignancies. However, it is associated with prolonged hematologic toxicity (PHT) that is unpredictable… read more here.
Keywords: hematologic toxicity; cell therapy; prolonged hematologic; toxicity ... See more keywords